Cytokinetics Inc

Lionheart Holdings Class A

HeartSciences Inc.

Verve Therapeutics

Amarin Corporation

Heartbeam, Inc.

Heartflow, Inc.

Esperion Therapeutics

Cardio Diagnostics Holdings Inc.

Dilution score: 18/100 (LOW), 24.0 months cash

Short interest: 13.29% of float, squeeze risk: MODERATE

1044 PubMed publications found for Cytokinetics

Racial and ethnic diversity in clinical studies reported to ClinicalTrials.gov, 2009-2024.

Oral Anticoagulation With or Without Antiplatelet Therapy in Chronic Coronary Syndrome: A Meta-Analysis of Randomized Trials.

Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial.

The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial.

Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic-Cardiodynamic Modeling to Support Safety and Efficacy.

Dilution score: 30/100 (MEDIUM), 25.8 months cash

1042 PubMed publications found for Cytokinetics

Short interest: 13.28% of float, squeeze risk: MODERATE

Short interest: 12.83% of float, squeeze risk: MODERATE

Characteristics of interventional clinical trials registered in ClinicalTrials.gov, 2018-2023.

1040 PubMed publications found for Cytokinetics

The emerging use of artificial intelligence in safety pharmacology and toxicology.

SW convergence: 50/100 (Neutral), 0 bullish / 0 bearish signals

1038 PubMed publications found for Cytokinetics

1036 PubMed publications found for Cytokinetics

The emerging use of artificial intelligence in safety pharmacology & toxicology.

Tricuspid Valve Academic Research Consortium-2 (TVARC-2): Trial Design and Endpoints.

Short interest: 12.02% of float, squeeze risk: MODERATE

1035 PubMed publications found for Cytokinetics

Congress: 1 buys, 0 sells (1 total trades)

Short interest: 12.03% of float, squeeze risk: MODERATE

1034 PubMed publications found for Cytokinetics

Balancing Clinical and Ethical Considerations Related to Placebo Use in Trials of Incretin-Based Therapies in Heart Failure.

Short interest: 12.15% of float, squeeze risk: MODERATE

SW convergence: 55/100 (Neutral), 1 bullish / 1 bearish signals

Dilution score: 20/100 (LOW), 27.9 months cash

Dilution score: 17/100 (LOW), 27.9 months cash

1027 PubMed publications found for Cytokinetics

Safety and efficacy of individualised exercise and NAD(+) precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial.

Tricuspid Valve Academic Research Consortium-2 (TVARC-2) Tricuspid Valve: Trial Design and Endpoints.

1026 PubMed publications found for Cytokinetics

<article class="bts-verified-summary" data-ticker="CYTK">
<p>Cytokinetics Inc (CYTK) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>CYTK has 14 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0001061983 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22CYTK%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR — 0001061983

Cytokinetics Inc (CYTK) — BioTechSigns Verified Summary

Cytokinetics Inc (CYTK) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

CYTK has 14 Form 4 insider filings recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR, 0001061983. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22CYTK%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11